A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 689-700

  Moyle, Graeme J ^a   Andrade Villanueva, Jaime ^b   Girard, Pierre Marie ^c   Antinori, Andrea ^d   Salvato, Patricia ^e   Bogner, Johannes R ^f   Hay, Phillip ^g   Santos, Jesús ^h   Astier, Ludovic ⁱ   Pans, Miranda ⁱ   Balogh, Agnes ⁱ   Biguenet, Sophie ⁱ  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e Diversified Medical Practices PA   (United States)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g ST GEORGE S HOSPITAL   (United Kingdom)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PLUS RITONAVIR; APOLIPOPROTEIN B; ATAZANAVIR PLUS RITONAVIR; FOSAMPRENAVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS RNA;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CANDIDIASIS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EYE JAUNDICE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; JAUNDICE; KIDNEY DISEASE; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEVENS JOHNSON SYNDROME; VIRUS INHIBITION;

ABDOMINAL FAT; ADULT; AGED; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROTEASE INHIBITORS; PYRIDINES; YOUNG ADULT;

EID: 84861674709     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2083     Document Type: Article

References (55)

1. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
2. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
3. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43. (Pubitemid 30123263)
4. Mallon PW, Miller J, Cooper DA, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971-979. (Pubitemid 36549708)
5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58. (Pubitemid 28190689)
6. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002; 31:50-55.
7. Blass SC, Ellinger S, Vogel M, et al. Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control. Eur J Med Res 2008; 13:209-214. (Pubitemid 351877691)
8. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-1667. (Pubitemid 30015713)
9. Grunfeld C, Rimland D, Gibert CL, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr 2007; 46:283-290. (Pubitemid 350287354)
10. Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008; 48:44-52. (Pubitemid 351600858)
11. Mynarcik DC, McNurlan MA, Steigbigel RT, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25:312-321. (Pubitemid 32107162)
12. Cofrancesco J, Freedland E, McComsey G. Treatment options for HIV-associated central fat accumulation. AIDS Patient Care STDS 2009; 23:5-18.
13. Mauss S, Schmutz G. [HIV-lipodystrophy syndrome]. Med Klin (Munich) 2001; 96:391-401. German.
14. Falusi OM, Aberg JA. HIV and cardiovascular risk factors. AIDS Read 2001; 11:263-268.
15. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
16. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-875. (Pubitemid 28121176)
17. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20:711-718. (Pubitemid 43884298)
18. Mallolas J, Podzamczer D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: The ATAZIP Study. J Acquir Immune Defic Syndr 2009; 51:29-36.
19. Soriano V, Garcia-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008; 61:200-205.
20. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007; 44:1484-1492. (Pubitemid 46801594)
21. Jackson A, Patel N, Lo G, et al. Effects of atazanavir or saquinavir once daily with ritonavir 100 mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal: a randomized open-label study. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 818.
22. Möbius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005; 39:174-180. (Pubitemid 40741115)
23. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
24. Busti AJ, Bedimo R, Margolis DM, et al. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med 2008; 56:539-544.
25. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-2144. (Pubitemid 39463678)
26. Noor MA, Flint OP, Maa JF, et al. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821. (Pubitemid 44358899)
27. Dubé MP, Shen C, Greenwald M, Mather K. No impairment of endothelial function of insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebocontrolled trial. Clin Infect Dis 2008; 47:567-574.
28. Stanley TL, Joy T, Hadigan CM, et al. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 2009; 23:1349-1357.
29. Molarius A, Sedell JC. Selection of anthropometric indicators for classification of abdominal fatness: a critical review. Int J Obes Relat Metab Disord 1998; 22:719-727. (Pubitemid 28359285)
30. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23:1109-1118.
31. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
32. Després JP. Health consequences of visceral obesity. Ann Med 2001; 33:534-541. (Pubitemid 33052274)
33. Collot-Teixeira S, De Lorenzo F, Waters L, et al. Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther 2009; 85:375-378.
34. Aberg J, Overton T, Gupta S, et al. METABOLIK (Metabolic Evaluation in Treatment-naives Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): comparison of the metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir over 12 weeks. 18th International AIDS Conference. 18-23 July 2010, Vienna, Austria. Abstract WEPE0111.
35. Skiest D, Cohen C, Khanlou H, et al. Randomized comparison of DRV/r vs ATV/r on serum lipids in HIV-positive persons on fully suppressive LPV/r or FPV/r with high serum triglycerides. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 817.
36. Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006; 41:590-597.
37. Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33:22-28. (Pubitemid 36547237)
38. Moyle G, Baldwin C, Comitis S, et al. Management of metabolic and body shape changes occurring during protease inhibitor (PI) therapy by substitution of PI with efavirenz in virologically controlled HIV-1 positive persons: a single arm observational cohort. J Acquir Immune Defic Syndr 2001; 28:399-401. (Pubitemid 33101296)
39. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-215. (Pubitemid 34755281)
40. Tebas P, Zhang J, Hafner R, et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother 2009; 63:998-1005.
41. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036. (Pubitemid 38591194)
42. Moyle GJ, Sabin CA, Cartledge J, et al. RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050. (Pubitemid 44611057)
43. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002; 147:173-180.
44. Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002; 103:137-142.
45. Lee GA, Mafong DD, Noor MA, et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004; 36:645-647. (Pubitemid 38552377)
46. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18. (Pubitemid 32424384)
47. Carr A. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735. (Pubitemid 36293626)
48. Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007; 45:286-297. (Pubitemid 47012375)
49. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008; 22:1719-1728.
50. Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997; 100:1166-1173.
51. Ross R, Rissanen J, Hudson R. Sensitivity associated with the identification of visceral adipose tissue levels using waist circumference in men and women: effects of weight loss. Int J Obes Relat Metab Disord 1996; 20:533-538. (Pubitemid 26174338)
52. Rattarasarn C, Leelawattana R, Soonthornpun S, et al. Regional abdominal fat distribution in lean and obese Thai type 2 diabetic women: relationships with insulin sensitivity and cardiovascular risk factors. Metabolism 2003; 52:1444-1447. (Pubitemid 37461112)
53. Lovejoy JC, De La Bretonne JA, Klemperer M, et al. Abdominal fat distribution and metabolic risk factors: effects of race. Metabolism 1996; 45:1119-1124. (Pubitemid 26300311)
54. Bacchetti P, Gripshover B, Grunfeld C, et al. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131.
55. Evans DJ, Murray R, Kissebah AH. Relationship between skeletal muscle insulin resistance, insulin mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography. J Clin Invest 1984; 74:1515-1525. (Pubitemid 15200247)